<DOC>
	<DOCNO>NCT00401245</DOCNO>
	<brief_summary>Desvenlafaxine succinate ( DVS SR ) serotonin norepinephrine reuptake inhibitor ( SNRI ) . It nonhormonal option treatment Vasomotor Symptoms ( VMS ) associate menopause . Nausea common adverse event observe clinical study main reason discontinuation first week therapy . Other adverse event ( headache , nausea , dizziness ) associate DVS SR note occur subject abruptly discontinue medication . The purpose study evaluate several titration taper regimen DVS SR ensure good tolerability profile start completion treatment . In addition , study provide long posttreatment follow-up ass symptom treatment discontinue .</brief_summary>
	<brief_title>The Effect Of Dose Titration And Dose Tapering On The Tolerability Of DVS SR In Women With Vasomotor Symptoms</brief_title>
	<detailed_description />
	<mesh_term>Desvenlafaxine Succinate</mesh_term>
	<criteria>Generally healthy , postmenopausal woman seek treatment hot flush . Meets 1 follow : At least 12 month spontaneous amenorrhea ; At least 6 month spontaneous amenorrhea serum folliclestimulating hormone ( FSH ) level &gt; 40 mIU/mL ; At least 6 week postsurgical bilateral oophorectomy ( without hysterectomy ) . Hysterectomized without bilateral oophorectomy serum FSH level &gt; 40 mIU/mL . History seizure disorder single childhood febrile seizure . History presence clinically important hepatic renal disease medical disease . Presence recent history major depressive disorder , bipolar disorder , psychotic disorder , generalize anxiety disorder require therapy .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>